Book a Meeting

BetterBet™ Anti-CD19 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP376) Datasheet

Target
CD19
Description
Anti-CD19 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19 molecule
Background
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Description
Anti-CD19 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.

Due to high homology between inhibitory FcγRIIB and activating FcγRIIA, no successful Fc engineering to selectively enhance FcγRIIB binding has been reported. Since FcγRIIA is expressed on platelet, antibody could crosslink platelets by binding to FcγRIIA expressed on platelet, and has a risk of inducing thrombosis. Therefore, generation of novel Fc variant (FcγRIIB Binding Enhanced Antibody) with selective enhancement of FcγRIIB binding is neccessary. Engineered FcγRIIB Binding Enhanced Antibody could increase efficacy by inducing inhibitory signal into immune cell with strong FcγRIIB binding, in addition to neutralization of immune-activating antigen.

Related Products

BetterBet™ Anti-CD19 Recycling Antibody (CAT#: AES-0622-ZP48)
Non-fucosylated Anti-Human CD19 (Denintuzumab) Therapeutic Antibody (CAT#: BioBet-105ZP)
Non-fucosylated Anti-Human CD19 (Taplitumomab) Therapeutic Antibody (CAT#: BioBet-100ZP)
Non-Fucosylated Anti-Human CD19 (3649-aFuc) Therapeutic Antibody (CAT#: BioBet-1674ZP)
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody (CAT#: BioBet-CB-030LX)
Non-fucosylated Anti-Human CD19 (Taplitumomab paptox) Therapeutic Antibody (CAT#: BioBet-103ZP)
ADCC-Enhanced Anti-Human CD19 (Tafasitamab) Antibody (CAT#: BioBet-CB-003LX)
Highly Galactosylated Anti-CD19 (Blinatumomab) Antibody (CAT#: BioBet-GA-010ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany